|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/17/23 BiondVax Pharmaceuticals Ltd. 10-K 12/31/22 85:12M EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.59M
2: EX-3.1 Articles of Association of Biondvax HTML 303K
Pharmaceuticals Ltd
3: EX-4.1 Description of Securities HTML 98K
6: EX-10.10 Employment Agreement Dated September 5, 2018, HTML 24K
Between Biondvax Pharmaceuticals Ltd. and Elad
Mark
7: EX-10.21 Amendment Agreement Dated August 9, 2022, to HTML 27K
Finance Contract Dated June 19, 2017 and as
Amended From Time to Time, by and Between Biondvax
Pharmaceuticals Ltd. and the European Investment
Bank
4: EX-10.8 Addendum to Employment Agreement Dated May 28, HTML 22K
2015, Between Biondvax Pharmaceuticals Ltd. and
Dr. Tamar-Ben Yedidia
5: EX-10.9 Addendum to Employment Agreement Dated April 1, HTML 22K
2012, Between Biondvax Pharmaceuticals Ltd. and
Dr. Tamar-Ben Yedidia
8: EX-14.1 Code of Conduct HTML 70K
9: EX-23.1 Consent of Kost Forer Gabbay & Kasierer, Certified HTML 23K
Public Accountant (Isr.), A Member of Ernst &
Young Global, Independent Registered Public
Accounting Firm for the Registrant
10: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
13: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
19: R1 Document And Entity Information HTML 93K
20: R2 Balance Sheets HTML 124K
21: R3 Balance Sheets (Parentheticals) HTML 32K
22: R4 Statements of Operations HTML 58K
23: R5 Statements of Operations (Parentheticals) HTML 33K
24: R6 Statements of Comprehensive Loss HTML 43K
25: R7 Statements of Changes in Shareholders? Equity HTML 67K
26: R8 Statements of Changes in Shareholders? Equity HTML 25K
(Parentheticals)
27: R9 Statements of Cash Flows HTML 97K
28: R10 General HTML 31K
29: R11 Significant Accounting Policies HTML 64K
30: R12 Prepaid Expenses and Other Receivables HTML 30K
31: R13 Fair Value Measurements HTML 33K
32: R14 Property, Plant and Equipment, Net HTML 33K
33: R15 Leases HTML 36K
34: R16 Other Payables HTML 29K
35: R17 Contingent Liabilities and Commitments HTML 29K
36: R18 Loan from Others HTML 40K
37: R19 Shareholders' Equity HTML 38K
38: R20 Share-Based Compensation HTML 59K
39: R21 Taxes on Income HTML 40K
40: R22 Basic and Diluted Net Loss Per Share HTML 34K
41: R23 Financial Income, Net HTML 32K
42: R24 Subsequent Events HTML 27K
43: R25 Accounting Policies, by Policy (Policies) HTML 113K
44: R26 Significant Accounting Policies (Tables) HTML 32K
45: R27 Prepaid Expenses and Other Receivables (Tables) HTML 30K
46: R28 Fair Value Measurements (Tables) HTML 31K
47: R29 Property, Plant and Equipment, Net (Tables) HTML 32K
48: R30 Leases (Tables) HTML 37K
49: R31 Other Payables (Tables) HTML 29K
50: R32 Share-Based Compensation (Tables) HTML 63K
51: R33 Taxes on Income (Tables) HTML 33K
52: R34 Basic and Diluted Net Loss Per Share (Tables) HTML 34K
53: R35 Financial Income, Net (Tables) HTML 32K
54: R36 General (Details) HTML 31K
55: R37 Significant Accounting Policies (Details) HTML 46K
56: R38 Significant Accounting Policies (Details) - HTML 47K
Schedule of straight-line basis over the useful
life of the assets at annual rates
57: R39 Significant Accounting Policies (Details) - HTML 30K
Schedule of fair value
58: R40 Prepaid Expenses and Other Receivables (Details) - HTML 30K
Schedule of prepaid expenses and other receivables
59: R41 Fair Value Measurements (Details) - Schedule of HTML 29K
assets measured at fair value
60: R42 Property, Plant and Equipment, Net (Details) HTML 26K
61: R43 Property, Plant and Equipment, Net (Details) - HTML 43K
Schedule of property, plant and equipment
62: R44 Leases (Details) HTML 28K
63: R45 Leases (Details) - Schedule of supplemental HTML 37K
balance sheet information related to operating
leases
64: R46 Leases (Details) - Schedule of right of use assets HTML 46K
over the remaining lease periods
65: R47 Other Payables (Details) - Schedule of other HTML 30K
payables
66: R48 Contingent Liabilities and Commitments (Details) HTML 34K
67: R49 Loan from Others (Details) HTML 67K
68: R50 Shareholders' Equity (Details) HTML 65K
69: R51 Share-Based Compensation (Details) HTML 44K
70: R52 Share-Based Compensation (Details) - Schedule of HTML 33K
fair value measurement of equity-settled share
options
71: R53 Share-Based Compensation (Details) - Schedule of HTML 64K
options granted to employees
72: R54 Share-Based Compensation (Details) - Schedule of HTML 42K
outstanding and exercisable options granted to
employees
73: R55 Share-Based Compensation (Details) - Schedule of HTML 40K
restricted shares activity
74: R56 Share-Based Compensation (Details) - Schedule of HTML 30K
total share-based compensation expense
75: R57 Taxes on Income (Details) HTML 28K
76: R58 Taxes on Income (Details) - Schedule of reduce HTML 40K
deferred tax assets
77: R59 Basic and Diluted Net Loss Per Share (Details) - HTML 29K
Schedule of computation of net loss per share
78: R60 Basic and Diluted Net Loss Per Share (Details) - HTML 32K
Schedule of diluted weighted average number of
shares outstanding
79: R61 Financial Income, Net (Details) - Schedule of HTML 48K
financial income expenses
80: R62 Subsequent Events (Details) HTML 31K
83: XML IDEA XML File -- Filing Summary XML 146K
81: XML XBRL Instance -- f10k2022_biondvax_htm XML 702K
82: EXCEL IDEA Workbook of Financial Reports XLSX 119K
15: EX-101.CAL XBRL Calculations -- adr-20221231_cal XML 86K
16: EX-101.DEF XBRL Definitions -- adr-20221231_def XML 592K
17: EX-101.LAB XBRL Labels -- adr-20221231_lab XML 1.27M
18: EX-101.PRE XBRL Presentations -- adr-20221231_pre XML 596K
14: EX-101.SCH XBRL Schema -- adr-20221231 XSD 220K
84: JSON XBRL Instance as JSON Data -- MetaLinks 321± 476K
85: ZIP XBRL Zipped Folder -- 0001213900-23-030228-xbrl Zip 477K
Exhibit 14.1
BIONDVAX PHARMACEUTICAL LTD.
CODE OF CONDUCT
Introduction
It is the policy of BiondVax Pharmaceuticals Ltd. (together with its subsidiaries, the “Company”) to conduct its affairs in accordance with all applicable laws, rules and regulations of the jurisdictions in which it does business. This Code of Business Conduct and Ethics (this “Code”) applies to the Company’s employees, officers and directors (each an “Associate”). This Code is designed to:
| ● | promote honest and ethical conduct by all of the Company’s Associates, including the ethical handling by such persons of actual or apparent conflicts of interest; |
| ● | promote full, fair, accurate, timely and understandable disclosure in the reports and documents the Company files with, or submits to, the U.S. Securities and Exchange Commission (“SEC”) and in other public communications made by the Company; |
| ● | promote compliance with applicable governmental laws, rules and regulations; |
| ● | ensure the prompt internal reporting to the appropriate person of violations of this Code; and |
| ● | ensure accountability for adherence to this Code. |
All the Associates of the Company are subject to this Code and are expected to adhere to and comply with those principles and procedures set forth in this Code which apply to them. All the Associates are expected to act with integrity and adhere to the highest standards of ethics and business conduct in dealing with each other and with the Company’s shareholders, customers, vendors, partners, service providers, competitors and all other third parties with whom an Associate has contact in the course of performing his or her job.
The Company will take such disciplinary or preventative action as it deems appropriate to address any existing or potential violation of this Code brought to its attention. To the extent this Code requires a higher standard than required by commercial practice or applicable laws, rules or regulations, we adhere to these higher standards.
Approvals and Waivers
Certain provisions of this Code require you to act, or to refrain from acting, unless prior approval is received from the appropriate person. Employees requesting approval pursuant to this Code should request such approval in writing from the Chairman of the Audit Committee of the Board of Directors. Approvals relating to executive officers and directors must be obtained from the Company’s Board of Directors. All other approvals may be granted by the Chairman of the Audit Committee of the Board of Directors, or such officer’s designee.
Other provisions of this Code require you to act, or to refrain from acting, in a particular manner and do not permit exceptions based on obtaining an approval. Waiver of those provisions relating to executive officers, senior financial officers and directors may only be granted by the Board of Directors.
Responsibility for Compliance
Responsibility of Company Associates
You are obligated to adhere to this policy in the performance of your job responsibilities.
When faced with a situation that requires an evaluation of whether something is considered proper business conduct, you can apply the following criteria: (i) Is the course of conduct legal? Is the course of conduct in accordance with the guidelines set forth in this Code and with Company policies and procedures? (ii) Would you or the Company be compromised or embarrassed if the situation were known by your co-workers or the public? Does the intended course of conduct have the appearance of impropriety?
If you are unable to provide a positive answer to both parts of (i) and a negative answer to both parts of (ii) with certainty, seek advice through the channels described in the immediately following section.
Note that failure to report a violation of this Code is in itself a violation of this Code.
Seeking advice or reporting non-compliance
If you suspect non-compliance, or have a question as to any aspect of this Code, including its interpretation, application or compliance therewith, regarding yourself or any other Associate of the Company, you must seek the advice of and report to the appropriate Company authority, such as your immediate supervisor or the Chairman of the Audit Committee of the Board of Directors. If for any reason you feel uncomfortable discussing your concerns or questions with such individuals, or if you are dissatisfied with their responses, seek advice from the Internal Auditor.
Mr. Adi Raviv (Chairman of the Audit Committee); adi.raviv@biondvax.com; Tel: +1-(917) 518-4568.
Yisrael Gewirtz (Internal Auditor); e-mail: Yisrael.Gewirtz@il.gt.com; Tel: +972-(0)3-710-6555. Cell: +972-(0)50-823-0438
The Company’s policy prohibits discrimination, harassment and retaliation against any Associate who in good faith provides any information or otherwise assists in any investigation or proceeding regarding any potential violation of this Policy.
Disciplinary action
The Company intends to prevent the occurrence of conduct not in compliance with the Code, applicable laws or regulations, or other policies, procedures and guidelines prepared by the Company and its business units and to prevent or halt any such conduct that may occur prior to its occurrence or as soon as reasonably possible after its discovery. Allegations of non-compliance with the Code will be investigated whenever necessary and evaluated at the proper level(s). Allegations of violations by a director or executive officer of the Company will be investigated by the Audit Committee (or another independent committee of the Board), who will report its findings to the Board of Directors. Allegations of violations by a person other than a director or executive officer will be investigated by the Internal Auditor, who will report its determinations to the CEO (or, if the allegation involves the CEO, the Chairman of the Audit Committee). Upon receipt of a determination that there has been a violation of this Code, the Board of Directors or (for persons other than executive officers or directors of the Company) the CEO will take such preventative or disciplinary action as it deems appropriate, including but not limited to, reassignment, demotion, or termination of employment. Criminal misconduct may be referred to the appropriate legal authorities for prosecution.
Reporting Potential Violations
If you think you are being asked to act or conduct business in an illegal, unethical, or otherwise inappropriate manner, or you suspect others of such behavior, immediately report your concerns through the appropriate channels described above. You will not be penalized for reporting what you believe, in good faith, to be a breach of the Code, even if it later become evident that no violation had occurred.
| 2 |
The Employment Relationship
Terms of employment
The Company employees are generally employed by the Company, either pursuant to an employment contract or other arrangement. Subject to applicable law, both the employee and the employer are legally allowed to terminate the employment at will. This Code or any part thereof may be revised from time to time at the Company’s discretion and is not and shall not be construed as a contract of employment.
Anti-discrimination and anti-harassment
The Company hires, pays, promotes, and makes other employment decisions based upon lawful factors, such as qualifications and performance, and without regard to gender, race, sex, color, religion, age, national origin, sexual orientation, disability or any other basis that is protected under applicable law.
Drugs, alcohol and smoking
The Company prohibits the illegal use, sale, purchase, transfer, possession or presence in one’s system of drugs, other than medically prescribed drugs, while on the Company’s premises.
The possession, consumption, purchase or sale of alcohol on Company premises is prohibited. Furthermore, no employee shall be under the influence of alcohol while performing Company business off Company premises. Any exception to this Policy for special situations, such as a Company party or event, must be approved by a Company officer, and even in such special situations, Company employees must exercise judgment and act responsibly.
In addition, persons whose positions with the Company require driving Company equipment or vehicles as a part of their work may not drive such equipment or vehicles while under the influence of alcohol.
Smoking is not permitted on Company premises.
Workplace violence
The Company does not tolerate (i) workplace violence or threats of violence committed by or against employees or property, (ii) any harassment or abuse (including sexual harassment), or (iii) any other form of bullying or intimidation in the workplace.
Conflict of interest and opportunities for personal gain
Associates must avoid relationships, activities or interests that conflict or appear to conflict with the best interests of the Company and must avoid any personal activity, investment or association that may interfere with using good judgment concerning the Company’s best interests. Associates may not exploit their position or relationship with the Company for personal gain. Associates have an obligation to promptly disclose to their supervisor, the internal auditor or the Chairman of the Audit Committee any relationship, activity or interest that could possibly involve or appear to involve an actual or potential conflict of interest. If you are unsure whether something is a conflict of interest, you are obligated to promptly disclose it to your supervisor.
Related party transactions
Associates should immediately inform the Chairman of the Audit Committee of the Board or the Internal Auditor at the outset of negotiations or contacts regarding a potential transaction between an entity or a person related to an Associate of the Company and in any event prior to completion of any such transaction (without regard to size or materiality).
Bribes, Kickbacks, Gifts or Other Types of Unusual Payments
You may never accept bribes, kickbacks, or other types of unusual payments from any organization or individual seeking to do business with, doing business with, or competing with the Company. You may accept gifts or entertainment of nominal value as part of the normal business process if public knowledge of your acceptance would cause the Company no conceivable embarrassment. In accordance with U.S. and other foreign laws, you are generally prohibited from directly or indirectly authorizing, offering, promising or giving anything of value to (i) a foreign governmental official and (ii) a physician or health care provider as a means of influencing or inducing such individual to obtain or retain business for the Company.
| 3 |
Fraud
You may not engage in fraudulent conduct, including any deliberate practice of deception in order to receive unfair or unlawful gain.
Outside employment or consulting
Employment as a consultant, employee, officer, or manager of another business organization requires prior written management approval. Outside employment or consulting must never interfere with your job performance, utilize Company property or facilities, involve the implicit or explicit sponsorship of the Company, or create the possibility of adverse publicity for the Company.
Political activity and contributions
Requiring anyone at Company to make a personal or corporate contribution to any candidate, political party, or holder of any governmental office is prohibited. You are free to participate in lawful political activity.
Financial reporting
All financial and other records of the Company are required to accurately and fairly reflect the Company’s assets, liabilities, revenues and expenses.
Company records and accounts
All Company records and accounts are the property of the Company. Company records and accounts must be maintained at all times in reasonable detail and in a manner that accurately reflects all business and financial transactions, including the disposition of assets. The destruction or falsification of a document in order to impede a litigation, governmental investigation, audit or examination is prohibited and may lead to prosecution for obstruction of justice.
Protection of the Company’s Property
All Associates should endeavor to protect the Company’s property, plant and other tangible and intangible assets. Company property should not be used for non-Company business, though incidental personal use may be permitted.
Expense accounts
The Company recognizes that it may have a responsibility to reimburse you for legitimate business expenses. Those expenses should be within reasonable limits and commensurate with the nature of the business assignment. You are expected to fully and clearly document business expenses and comply any travel or other policy that applies to your business unit.
Associate privacy
Company information about Associates is confidential and only those with a legitimate, work-related need may access such information.
Proprietary information and intellectual property
Proprietary business, technical, personal information or any trade secret of the Company and its Associates, customers and suppliers is considered confidential and must be safeguarded. Intellectual property developed by you or by others for the Company, or for which the Company has secured rights from others, should be used only for the benefit of the Company. Accordingly, all intellectual property rights derived from confidential information or other materials made, originated or developed by the Company employees and/or officers shall belong exclusively to the Company, and the employees and/or officers who are the inventors or developers of such intellectual property rights shall have no rights or benefits therein or deriving therefrom. You may not disclose proprietary information of the Company, its Associates, customers, former Associates, former customers or suppliers. These prohibitions continue even if you cease being an Associate of the Company for any reason.
| 4 |
Corporate data security
Corporate data refers to all information collected, created, processed and/or maintained in the normal course of the Company’s business. The data may be in manual form (such as verbal, handwritten, typed onto hard copy, microfilmed, photocopied or computer printouts), electronic form (such as e-mails, voice-mails, computer memory, cloud storage, magnetic tape, cassette, disk, or diskette), or Company specific information included in computer applications programs, personal computing software, or operating system software.
All the Company Associates and any other person having physical or electronic access to corporate data are responsible for safeguarding corporate data by keeping such corporate data confidential.
Electronic communications
You may not access or use the Company’s electronic and wire communications systems without appropriate authority. No individual shall use the passwords or codes of another individual in order to gain access to that individual’s e-mail, voice mail, ERP system, automated or control system, or Internet communications on the Company’s systems unless first authorized to do so by that individual or the Company. These systems are provided for Company business, and only occasional personal use of the systems is permissible. Occasional personal use means minimal and infrequent use that does not interfere with the Company business or job performance. The Company’s systems may not be used to access or transmit material that could embarrass, harass, or offend the Company or other persons.
Additional rules and procedures regarding electronic communications are set forth in the Company’s computer policy.
External communications
Requests for financial or business information, for interviews with any the Company Associates including comments or responding to requests relating to the Company or its business, or the issuance of any press releases by any Company Associate must be referred to the CEO.
Public disclosure requirements
All reports and submissions (“Reports”) of the Company to the SEC and NASDAQ must comply with applicable legal and exchange requirements and may not contain material misstatements or omit material facts. Each director, officer and employee who is involved in the Company’s disclosure process must: (a) be familiar with and comply with the Company’s disclosure controls and procedures and its internal control over financial reporting; and (b) take all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and business condition of the Company provide full, fair, accurate, timely and understandable disclosure. Each director, officer and employee who contributes in any way to the preparation or verification of the Company’s financial statements and other financial information must ensure that the Company’s books, records and accounts are accurately maintained. Each director, officer and employee must cooperate fully with the Company’s accounting and internal audit departments, as well as the Company’s independent public accountants and counsel.
Relationships with Business Entities and Authorities
Product quality
We are committed to making safe quality products. We expect each Company employee and/or officer to contribute to these standards by providing high quality work, being fully familiar with applicable laws and regulations that are pertinent to their areas of responsibility and participating in training programs provided by the Company covering broad ranges of activities. The Company maintains a Quality Management System that documents all of the Company policies, procedures and controls applicable to employees.
Employees and officers are also encouraged to exert diligence in identifying and preventing practices that could impair product quality, safety or compliance with law.
| 5 |
Economic Sanctions
Company Associates must comply with the applicable laws and regulations of the United States, Israel and other relevant jurisdictions relating to economic and trade sanctions and embargoes against certain countries or entities. This includes refraining from indirect facilitation of a prohibited transaction.
Foreign corrupt practices and anti-boycott laws
In accordance with the laws of the United States, Israel and other relevant jurisdictions, Company Associates are prohibited from directly or indirectly authorizing, offering, promising or giving anything of value to a foreign governmental official as a means of influencing or inducing the official to obtain or retain business for the Company. Company Associates are also required to comply with applicable corrupt practices laws and anti-boycott laws that prohibit participation in certain foreign boycotts.
Securities laws compliance and insider trading
All the Company Associates must strictly obey all laws that prohibit the trading of securities based on prior knowledge of “material non-public information” about the Company. You (and your relatives) may not trade Company stock or engage in any other action to take advantage of or pass on to others such information, nor recommend to others that they trade the Company’s stock until such information ceases to be “material non-public information”. These restrictions also apply to any trading, including securities of other companies, based on material, non-public information about customers, competitors or business partners or suppliers of the Company, either when trading the Company’s securities or the securities of such other companies as well.
Unfair trade practices and fair dealing
The company must comply with all applicable fair competition and antitrust laws. Such laws are intended to ensure that businesses compete fairly and honestly and prohibit conduct seeking to reduce or restrain competition. All Company Associates must comply with applicable laws in their place of employment and the laws of other applicable jurisdictions that prohibit unfair or deceptive business acts and practices, as well as unfair competition.
Environmental protection
The Company is committed to full compliance with all applicable environmental protection laws and expects your individual cooperation.
Health and safety
Associates must observe safe practices on their jobs, report any injury or accident at work promptly. Specific rules and procedures regarding safety are set forth in the following safety policies of the Company:
Document Name | Document Number | |
| תוכניתבטיחותוגיהותלמעבדה | SFT-0000532 | |
| תוכניתבטיחותוגיהותלמעבדה | SFT-0000532 | |
| תוכניתבטיחותוגיהותלמעבדה | SFT-0000532 | |
| נוהלחירום | SFT-0000534 | |
| נוהלחירום | SFT-0000534 | |
| נוהלעבודהבטוחהעםגורמיםביולוגיים | SFT-0000535 | |
| נוהלעבודהבטוחהעםגורמיםביולוגיים | SFT-0000535 | |
| נוהלעבודהעםחומריםכימיים | SFT-0000536 | |
| נוהלעבודהעםחומריםכימיים | SFT-0000536 | |
| נוהלדיווחוחקירהשלאירוע(תאונה.כמעט תאונה) | SFT-0000537 | |
| נוהלדיווחוחקירהשלאירוע(תאונה.כמעט תאונה) | SFT-0000537 | |
| נוהלבטיחותכללי | SFT-0000538 | |
| נוהלבטיחותכללי | SFT-0000538 | |
| תוכניתלניהולבטיחותבמפעל | SFT-0000977 | |
| נוהלטיפולבחומריםרעיליםוחומריםכללים | QAP-047 |
| 6 |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/30/24 Scinai Immunotherapeutics Ltd. F-3 4:511K EdgarAgents LLC/FA 1/02/24 Scinai Immunotherapeutics Ltd. 424B3 1:308K EdgarAgents LLC/FA 12/22/23 Scinai Immunotherapeutics Ltd. F-1/A 2:378K EdgarAgents LLC/FA 10/30/23 Scinai Immunotherapeutics Ltd. F-1 5:761K EdgarAgents LLC/FA 9/19/23 Scinai Immunotherapeutics Ltd. 424B5 1:410K EdgarAgents LLC/FA 8/28/23 BiondVax Pharmaceuticals Ltd. 424B2 1:254K EdgarAgents LLC/FA 8/18/23 BiondVax Pharmaceuticals Ltd. F-3 5:437K EdgarAgents LLC/FA 4/17/23 BiondVax Pharmaceuticals Ltd. S-8 4/17/23 4:151K EdgarAgents LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/14/22 BiondVax Pharmaceuticals Ltd. F-1/A 8:1M EdgarAgents LLC/FA 3/28/22 BiondVax Pharmaceuticals Ltd. 20-F 12/31/21 91:41M EdgarAgents LLC/FA 11/22/21 BiondVax Pharmaceuticals Ltd. 6-K 11/22/21 3:465K EdgarAgents LLC/FA 5/13/21 BiondVax Pharmaceuticals Ltd. 20-F 12/31/20 88:7.6M EdgarAgents LLC/FA 6/12/20 BiondVax Pharmaceuticals Ltd. 20-F 12/31/19 91:8.1M EdgarAgents LLC/FA 4/23/19 BiondVax Pharmaceuticals Ltd. 6-K 4/23/19 2:1.4M EdgarAgents LLC/FA 4/30/18 BiondVax Pharmaceuticals Ltd. 20-F 12/31/17 84:8.5M EdgarAgents LLC/FA 6/19/17 Scinai Immunotherapeutics Ltd. 6-K 6/19/17 3:451K EdgarAgents LLC/FA 4/06/15 Scinai Immunotherapeutics Ltd. F-1/A 7:9.1M EdgarAgents LLC/FA 12/29/14 Scinai Immunotherapeutics Ltd. F-1 20:11M EdgarAgents LLC/FA |